Global Electroceuticals Market

Electroceuticals Market Size, Share, Growth Analysis, By Product (Cardiac Pacemakers & Implantable Cardioverter Defibrillators, Retinal Implants), By Type (Implantable Electroceutical Devices, Noninvasive Electroceutical Devices), By Application, By Region - Industry Forecast 2024-2031


Report ID: SQMIG35A2542 | Region: Global | Published Date: December, 2024
Pages: 157 | Tables: 93 | Figures: 75

Electroceuticals Market Insights

Global Electroceuticals Market size was valued at USD 23.9 billion in 2022 and is poised to grow from USD 25.57 billion in 2023 to USD 43.94 billion by 2031, growing at a CAGR of 7.0% during the forecast period (2024-2031). 

The past several years have seen a rapid acceleration in medical technology, which has changed therapies and medicine. As a result, the market for electroceuticals has grown significantly. Over the course of the forecast period, rapid developments in the healthcare sector and the spread of technology in medical applications are anticipated to drive the market for electroceuticals.

Over the next four years, it is anticipated that rising R&D spending, an ageing population, a high prevalence of chronic diseases, swift medical technology advancements, and rising awareness and acceptance of alternative medicine will all have a favourable impact on market growth. The demand for non-invasive electroceutical devices is anticipated to outpace that of implantable electroceutical devices due to the growing acceptance of less invasive techniques. But during the projection period, strict regulatory requirements, frequent product recalls, lengthy approval processes, and high costs are anticipated to be the main challenges that could limit the potential of the electroceuticals market.

Cardiovascular illnesses are becoming more common around the world, and this is anticipated to boost the growth of the electroceuticals market over the course of the projected period. The use of electroceuticals in the treatment of various cardiovascular illnesses is expected to increase during the coming years. Through the projection period, implantable cardioverter defibrillators are anticipated to experience strong demand.

The rise of infectious and chronic diseases worldwide during the past few decades has increased the focus on healthcare. The need for additional research and development in the healthcare sector has consequently increased, as has the desire for innovative therapies. Governments are starting initiatives and providing financing to boost research and development, which is anticipated to improve the market potential for electroceuticals during the following four years.

US Electroceuticals Market  is poised to grow at a sustainable CAGR for the next forecast year.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Electroceuticals Market size was valued at USD 23.9 billion in 2022 and is poised to grow from USD 25.57 billion in 2023 to USD 43.94 billion by 2031, growing at a CAGR of 7.0% during the forecast period (2024-2031). 

The market is fragmented in nature. The prominent players operating in the market are constantly adopting various growth strategies in order to stay afloat in the market. Product launches, innovations, mergers, and acquisitions, collaborations and partnerships, and intensive R&D are some of the growth strategies that are adopted by these key players to thrive in the competitive market. The key market players are also constantly focused on R&D in order to supply industries with the most efficient and cost-effective solutions. 'Medtronic ', 'Boston scientific corporation ', 'Abbott ', 'Livanova Plc ', 'Cochlear Ltd. ', 'Microport Scientific Corporation ', 'Sonova ', 'Nevro Corp. ', 'Axonics, Inc. ', 'Neuronetics ', 'Electrocore, Inc. ', 'Neuropace, Inc. ', 'Biotronik ', 'Medico S.R.L. ', 'Zhejiang Nurotron Biotechnology Co., Ltd. ', 'Med-EL ', 'Aleva Neurotherapeutics ', 'Neurosigma, inc. ', 'Biowave Corporation ', 'Soterix Medical Inc '

One of the primary factors driving the growth of the global electroceuticals market is the rising prevalence of cardiovascular illnesses. Cardiovascular illnesses are thought to be one of the leading causes of death around the world. According to the World Health Organization, cardiovascular disease kills more than 17.3 million people every year. Furthermore, by 2030, the global number of deaths due to cardiovascular illnesses is expected to reach 23.6 million. Cardiovascular illnesses affect 31% of the global population, with low and middle-income nations accounting for 80% of all deaths. According to the American Heart Society, cardiovascular disease killed over 800,000 people in the United States. This creates significant scope for the growth of the global electroceuticals industry during the forecast period. Furthermore, significant product launches by the key players operating in the market are considered another major aspect that drives the growth of the global electroceuticals market in the upcoming years.

The electroceuticals market has a large number of market players globally. The market players offer a broad product portfolio of electroceuticals for the treatment of diseases. The prominent players functioning in the global electroceutical market include Medtronic plc (Ireland), Boston Scientific Corporation (US), Abbott Laboratories, Inc. (the US), LivaNova PLC (UK), Cochlear Ltd. (Australia), MicroPort Scientific Corporation (China), Sonova Group (Switzerland), Nevro Corp. (US), BIOTRONIK (Germany), NeuroSigma, Inc. (the US), BioControl Medical (Israel), and tVNS Technologies GmbH (Germany) among many others. These players are continuously contributing to the growth of the market by adopting various growth strategies such as technological advancements and developments, product launches, mergers and acquisitions, and joint ventures among others to drive the growth of the market during the forecast period. Some of the recent activities by the company in the electroceutical industry include: in March 2021, Medtronic plc (Ireland) received US FDA approval for its Intellis Platform with Differential Target Multiplexed (DTM) programming to treat chronic intractable back and leg pain. While, in January 2021, Boston Scientific Corporation (US) received US FDA approval for its Vercise Genus Deep Brain Stimulation System.

Based on the region, the Global Electroceuticals Market is segmented into North America, Europe, Asia-Pacific, South America, and MEA. In 2021, the North American region is projected to hold the most substantial share of more than 32.0% in the global market. The presence of a significant number of players and government as well as non-government organizations emphasizing the electroceuticals is the prominent factor that contributes to the growth of the Electroceuticals Industry in the region. Increased healthcare spending is another factor that contributes to the growth of the regional Electroceuticals market. In the region, the US has the highest healthcare spending.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Electroceuticals Market

Report ID: SQMIG35A2542

$5,300
BUY NOW GET FREE SAMPLE